23 May 2026
How cartilage is maintained — and what a 2026 study of the protein SHP adds
It's easy to picture cartilage as a fixed cushion that slowly wears thin. In reality it's living tissue. The cells inside it, called chondrocytes, continually make new matrix and break old matrix down. Osteoarthritis involves that balance tipping towards breakdown.
Researchers are trying to understand what controls that balance. A study published in Nature Communications in 2026 looked at one protein that may be part of the picture.
What the study looked at
The protein is called small heterodimer partner, or SHP. The researchers wanted to know whether it influences the enzymes that break down cartilage — in particular two called MMP-3 and MMP-13 — through a signalling pathway known as IKKβ/NF-κB.
Study at a glance: SHP and cartilage breakdown in osteoarthritis
Study type: Laboratory and animal study
Who was studied: Cartilage from 9 people having knee replacement for osteoarthritis (damaged and less-damaged areas of the same joints); male mice with surgically induced knee osteoarthritis
What it found: SHP levels were lower in damaged human cartilage than in less-damaged cartilage from the same joints. Mice lacking SHP developed more severe joint damage and higher levels of cartilage-degrading enzymes, and delivering the SHP gene into the joint reduced damage in the mouse model
What it does not establish: That SHP falls as osteoarthritis progresses over time in people, that raising SHP helps people, or that anything you eat or take affects SHP. It studied male mice only
Did it test LYVA Flex: No
Kang E-J et al. Small heterodimer partner protects against osteoarthritis by inhibiting IKKβ/NF-κB-mediated matrix-degrading enzymes in chondrocytes. Nature Communications 2026;17:4270. doi:10.1038/s41467-026-69864-5
Why it's interesting
The study adds a piece to a large puzzle: how cartilage cells decide between building and breaking down. Understanding those control points is how new treatments are eventually found.
What it doesn't tell us
- It isn't a treatment. Gene delivery into joints is an experimental laboratory technique.
- The human part is small: tissue from nine people, all of whom already had advanced osteoarthritis.
- It says nothing about the gut. The study didn't look at the gut, gut bacteria or diet, so it can't be used to connect them to SHP.
- It doesn't show that any plant compound, food or supplement changes SHP or protects cartilage.
A note on how we use research
An earlier version of this article linked SHP to the gut. The study doesn't make that link, so we've removed it. We'd rather publish less, accurately, than more, loosely.
Explore how we are developing LYVA Flex: read the science or join the waitlist.
This article is for general information only. It is not medical advice. LYVA Flex is a food supplement, not a medicine. If you have a joint condition or take medication, speak to your GP or physiotherapist.
— William Tyler-Street, Founder